System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Marianne Leheurteur is an expert in Oncology at Centre Henri Becquerel (France). Marianne Leheurteur has authored 119 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 3 of them ongoing. SLR score: 337 (community average: 125). How the SLR is computed.

LeadR Profile

Marianne Leheurteur Centre Henri Becquerel France
337 ScienceLeadR Reputation 337

Unlock

Register Login
Network Map

Oncology

Subspecialties: Geriatrics - Dermatology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 119

Citations

Citations: 2 758 1st author: 0 Last author: 1 Unique author: 0

Main journals

Ann Oncol 21
J Clin Oncol 13
Cancer Res 11
Eur J Cancer 10
Breast 9

Best Journals

Ann Oncol 8
J Clin Oncol 6
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.
PMID 42301385 — triple negative breast neoplasms, breast neoplasms, drug therapy, chemotherapy		Breast Cancer20260
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.
PMID 41558201 — breast neoplasms, neoplasms, inflammatory breast neoplasms, multiple chronic conditions, drug therapy, breast, therapeutics, chemotherapy		ESMO Open20260
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.
PMID 41297161 — lymph nodes, breast neoplasms, neoplasms, immunotherapy, lymph, breast		ESMO Open20251
Correction: Analysis of the impact of the COVID-19 pandemic on the stage at diagnosis in breast cancer patients at a French comprehensive cancer centre, through two different methods: a preliminary study.
PMID 40983724 — breast neoplasms, neoplasms, covid-19, breast, diagnosis, pandemics		Breast Cancer Res Treat20250
Prognostic value of circulating HER2 extracellular domain in patients with HER2-positive metastatic breast carcinoma treated with TDM-1 (trastuzumab emtansine).
PMID 40754555 — breast neoplasms, neoplasms, biomarkers, maytansine, ado-trastuzumab emtansine, breast, multivariate analysis, trastuzumab		Clin Transl Oncol20250

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 6
N/A 3
Phase 1 1
Phase 3 1

By status:

Completed 4
Recruiting 4
Unknown 2
Active not recruiting 1

By type:

Interventional 9
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 2
multicentric5to9 1
multicentricup10 6

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HRD Tests for Ovarian cancER
NCT06152731 — recombination, genetic, poly(adp-ribose) polymerase inhibitors, homologous recombination, ovary, neoplasms, drug therapy, ovarian neoplasms, therapeutics, chemotherapy, carcinoma		Phase 2Recruiting2024
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER HER2 Breast Cancer With an ESR1 Mutation
NCT05696626 — fulvestrant, estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, breast, therapeutics, mutation, men, women		Phase 3Recruiting2023
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
NCT04985266 — injections, anastrozole, fulvestrant, breast neoplasms, neoplasms, letrozole, tablets, solutions, breast, drug tapering, therapeutics, injections, intramuscular, dna, tamoxifen		Phase 2Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS